OPKO HEALTH, INC.
OPK evidence brief
What we can confirm
- BioSniper Score:
- 7.8 / 10
- Market Cap:
- $1.12B
- Lead Asset:
- mdx2001 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for OPK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OPK
OPKO Health is a diversified healthcare company with a pharmaceutical business featuring NGENLA (somatrogon-ghla), a once-weekly human growth hormone injection partnered with Pfizer, and a diagnostics segment, while holding $300.8M in cash as of 2026-06-30 [sec].
Key risk: Operating losses persist
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.12B
Cash Runway
—
Lead Asset
mdx2001 (Phase 1/Phase 2)
Next Catalyst
Patent_Expiry · Mar 14, 2034Financial data as of Jun 30, 2026.
Tracking 9 pipeline candidates · 8 clinical trials · 1 catalyst for OPKO HEALTH, INC..
OPKO Health is a diversified healthcare company with a pharmaceutical business featuring NGENLA (somatrogon-ghla), a once-weekly human growth hormone injection partnered with Pfizer, and a diagnostics segment, while holding $300.8M in cash as of 2026-06-30 [sec].
- Cash & equivalents of $300.8M as of 2026-06-30 [sec].
- Total revenue of $163.6M and net income of -$8.4M as of 2026-06-30 [sec].
- NGENLA (somatrogon-ghla) approved in over 50 markets including the US, EU, Japan, Australia, and Canada [sec · filed 2026-08-28].
- Subsidiary ModeX Therapeutics focuses on multi-specific immune therapies for cancer and infectious diseases [sec · filed 2026-08-28].
- Pipeline candidate OPK-88006 (oxyntomodulin) for MASH is in Phase 1/Phase 2 with partners LeaderMed Health Group and Entera Bio [pipeline].
What works
- NGENLA has secured regulatory approvals in more than 50 markets worldwide, including the US and EU, indicating broad commercial potential [sec · filed 2026-08-28].
- The company operates revenue-generating pharmaceutical platforms in Spain, Ireland, Chile, and Mexico that contribute to positive cash flow [sec · filed 2026-08-28].
- Cash and equivalents of $300.8M as of 2026-06-30 provide a substantial runway for operations and debt service [sec].
What to weigh
- Net income was negative at -$8.4M as of 2026-06-30, indicating ongoing operating losses [sec].
- Future cash requirements depend on uncertain factors including product approvals, commercial success of Rayaldee and Mazdutide, and BioReference's financial performance [sec · filed 2026-08-28].
- Milestone and royalty payments from partners are subject to risks and uncertainties inherent in drug development and commercialization [sec · filed 2026-08-28].
From the filings
Quoted directly from source documents.
NGENLA approvals in over 50 markets
“Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of children and adolescents, as young as three years of age, with growth disturbance due to insufficient secretion of growth hormone have been secured in more than 50 markets worldwide, including in the United States, European Union Member States, Japan, Canada, and Australia under the brand name NGENLA”
SEC filings · August 28, 2026
Cash sufficiency for 12+ months
“We believe that the cash, cash equivalents and restricted cash on hand on March 31, 2026 are sufficient to meet our anticipated cash requirements for operations and debt service beyond the next 12 months.”
SEC filings · August 28, 2026
Phase 3 somatrogon height velocity results
“HV at month 12 was 10.10 cm/year for somatrogon-treated subjects and 9.78 cm/year for somatropin-treated subjects, with a treatment difference (somatrogon-somatropin) of 0.33 (95% CI: -0.24, 0.89).”
Catalysts · June 16, 2022
Catalyst timeline
- 2034-03-14 · Patent_Expiry · CALCIFEDIOL — Patent expiry for NDA208010 (Calcifediol) may open the market to generic competition.
Risks & what to watch (3)›
Key risks
- Operating losses persist — Net income of -$8.4M as of 2026-06-30 indicates ongoing losses [sec].
- Dependence on partner milestones — Milestone and royalty payments are subject to drug development risks and uncertainties [sec · filed 2026-08-28].
- Cash may be needed sooner — Company may require additional funds if it acquires assets or accelerates programs [sec · filed 2026-08-28].
What to watch
- Commercial ramp of NGENLA and Rayaldee sales [sec · filed 2026-08-28].
- Progress of OPK-88006 (oxyntomodulin) Phase 1/Phase 2 trial for MASH [pipeline].
- BioReference's financial performance and its impact on overall results [sec · filed 2026-08-28].
- ModeX Therapeutics pipeline advancement in immuno-oncology and infectious diseases [sec · filed 2026-08-28].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run OPKO HEALTH, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OPKO HEALTH, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.54 · 0% dilution
Lead: Approved
9 candidates
1 upcoming, next in ~2708d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
233
Total value held
$227.1M
| Holder | Shares | Value |
|---|---|---|
| rubric capital management lp | 47,791,243 | $54.5M |
| blackrock, inc. | 36,232,223 | $41.3M |
| vanguard portfolio management llc | 14,769,719 | $16.8M |
| vanguard capital management llc | 14,499,164 | $16.5M |
| geode capital management, llc | 11,301,501 | $12.9M |
| state street corp | 9,501,377 | $10.8M |
| goldman sachs group inc | 7,675,026 | $8.7M |
| ubs group ag | 6,071,432 | $6.9M |
| whitefort capital management, lp | 4,253,340 | $4.8M |
| northern trust corp | 3,619,346 | $4.1M |
Showing top 10 of 233 institutional holders of OPKO HEALTH, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 7.8%
- Days to cover
- 12.7
- Shares short
- 33,615,361
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OPK short interestGovernance
Frequently asked questions
What is the AI investment thesis for OPKO HEALTH, INC.?
OPKO Health is a diversified healthcare company with a pharmaceutical business featuring NGENLA (somatrogon-ghla), a once-weekly human growth hormone injection partnered with Pfizer, and a diagnostics segment, while holding $300.8M in cash as of 2026-06-30 [sec].
What is OPKO HEALTH, INC.'s lead drug candidate?
OPKO HEALTH, INC.'s most advanced tracked candidate is mdx2001 (Phase 1/Phase 2) for solid tumors.
What is OPKO HEALTH, INC.'s next catalyst?
OPKO HEALTH, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA208010" — expected March 14, 2034.
Who is the CEO of OPKO HEALTH, INC.?
Dr. Phillip Frost M.D., Ph.D. is the chief executive officer of OPKO HEALTH, INC. (OPK).
Where is OPKO HEALTH, INC. headquartered?
OPKO HEALTH, INC. (OPK) is headquartered in Miami, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.